QuidelOrtho Eyes $1.5B Sale of Its Testing Division
QuidelOrtho is reportedly planning to divest its testing unit for $1.5 billion, according to the Financial Times.
QuidelOrtho, the diagnostics company formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, is reportedly moving to shed a major business unit in a deal valued at approximately $1.5 billion, according to a report from the Financial Times cited by Seeking Alpha. The planned divestiture signals a significant strategic pivot for a company that has been navigating a challenging post-pandemic landscape for diagnostics makers.
The move reflects broader pressures facing the diagnostics sector, where demand for COVID-19 testing — once a powerful revenue engine for companies like Quidel — has fallen sharply from its pandemic-era peak. Companies across the space have been forced to reassess their portfolios, separating high-growth or core assets from units that may command stronger valuations as standalone businesses or under different ownership.
Read more Singer Apologizes After Lyric Sparks Hometown Theft Wave →
A $1.5 billion transaction of this scale would represent a meaningful balance sheet event for QuidelOrtho, potentially freeing capital to pay down debt, invest in core product lines, or return value to shareholders. The company has carried a substantial debt load following the terms of its merger, making a well-priced asset sale particularly consequential for its financial flexibility going forward.
While the specific buyer and the precise unit involved were not detailed in the available reporting, deals of this nature in the diagnostics space typically attract interest from private equity firms and larger healthcare conglomerates seeking to build out testing capabilities. The outcome will likely be closely watched as a barometer of how the market values diagnostics assets in a normalized, post-COVID environment.
Continue reading at SeekingAlpha.
